摘要
目的 对比吉西他滨与吡柔比星膀胱灌注预防非肌层浸润性膀胱癌（NMIBC）经尿道膀胱肿瘤电切术（TURBT）后复发的效果和安全性。方法 将行TURBT后的79例NMIBC患者随机分为吉西他滨组39例和吡柔比星组40例,于术后1周开始分别采用吉西他滨和吡柔比星规律膀胱灌注,比较两组的肿瘤复发率、无复发生存时间及化疗副作用发生情况。结果 随访12-32个月,吉西他滨组及吡柔比星组1年复发率分别为7.7%（3/39）、17.5%（7/40）,32个月累积复发率分别为12.8%（5/39）、25.0%（10/40）,两组1年复发率及累积复发率比较,差异无统计学意义（P〉0.05）。吉西他滨组及吡柔比星组患者的无复发生存时间分别为（29.57±1.03）个月和（21.31±4.70）个月,吉西他滨组无复发生存时间长于高于吡柔比星组（P〈0.05）。吉西他滨组膀胱刺激症状及血尿发生率低于吡柔比星组（P〈0.05）。结论 吉西他滨膀胱灌注预防NMIBC术后复发疗效满意,不良反应轻,值得临床应用。
Objective To compare the efficacy and safety between intra-bladder perfusion with gemcitabine and pirarubicin for preventing the recurrence of non-muscle invasive bladder cancer after transurethral resection of bladder tumor（TURBT）. Methods Seventy-nine patients with non-muscle invasive bladder cancer after TURBT were randomly divided into gemcitabine group （n = 39） and pirarubicin group （n =40）. The gemcitabine group and pirarubicin group received regular intra-bladder perfusion with pirarubicin and gemcitabine after one week of TURBT respectively. The tumor recurrence rate, recurrence-free survival time and adverse reactions of chemotherapy were compared between the two groups. Results The patients received follow-up of 12 -32 months. The one-year recurrence rates of the gemcitabine group and piraurbicin group were 7.7% （3/39） and 17.5% （7/40） respectively,the 32-month cumulative recurrence rates of the gemcitabine group and pirantbicin group were 12.8% （5/39） and 25.0% （10/40） respectively. There was no statistical difference in the one-year recurrence rate or 32-month cumulative recurrence rate between the two groups（ P 〉 0. 05 ）. The recurrence-free survival times of the gemcitabine group and pirarubicin group were （29.57± 1.03 ） months and （21.31 ± 4.70） months respectively, and the time of the gemcitabine group was longer than that of the pirarubicin group（ P 〈 0.05 ）. The incidence rates of urinary disorders and hematuresis in the the gemcitabine group were lower than those in the pirarubicin group（ P 〈 0.05 ）. Conclusion Intra-bladder perfusion with gemcitabine can obtain a satisfied efficacy and has slight adverse reactions for preventing postoperative recurrence of non-muscle invasive bladder cancer, and is worthy of clinical application.
出处
《广西医学》
CAS
2016年第9期1260-1262,共3页
Guangxi Medical Journal
关键词
膀胱癌
吉西他滨
吡柔比星
膀胱灌注
经尿道膀胱肿瘤电切术
Bladder cancer
Gemcitabine
Pirarubicin
Intra-bladder perfusion
Transurethral resection of bladder tumor
